Evidence map›Paper›PMID 37174687›Full record

ArticleCells2023

CRMP2 Participates in Regulating Mitochondrial Morphology and Motility in Alzheimer's Disease.

Tatiana Brustovetsky, Rajesh Khanna, Nickolay Brustovetsky

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Tatiana BrustovetskyDepartment of Pharmacology and Toxicology, Indiana University School of Medicine, 635 Barnhill Drive, Medical Science Building, Room 362, Indianapolis, IN 46202, USA.
Rajesh KhannaDepartment of Molecular Pathobiology, New York University, New York, NY 10010, USA.ORCID 0000-0002-9066-2969
Nickolay BrustovetskyDepartment of Pharmacology and Toxicology, Indiana University School of Medicine, 635 Barnhill Drive, Medical Science Building, Room 362, Indianapolis, IN 46202, USA.
Indiana University School of MedicineNew York University · US

Funding

CRMP2, mitochondria, and Huntington’s diseaseR01NS098772 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI BRUSTOVETSKY, NICKOLAY, KHANNA, RAJESH · 2017 to 2021
$2.8M
CRMP2, Nav1.7 sodium channel, and chronic painR01DA042852 · NIDA · UNIVERSITY OF ARIZONA · PI KHANNA, RAJESH · 2017 to 2021
$1.9M
NIDA NIH HHS R01 DA042852NIH HHS R01 DA042852NIH HHS R01 NS098772NINDS NIH HHS R01 NS098772
6 · The paper itself

Abstract

Mitochondrial bioenergetics and dynamics (alterations in morphology and motility of mitochondria) play critical roles in neuronal reactions to varying energy requirements in health and disease. In Alzheimer's disease (AD), mitochondria undergo excessive fission and become less motile. The mechanisms leading to these alterations are not completely clear. Here, we show that collapsin response mediator protein 2 (CRMP2) is hyperphosphorylated in AD and that is accompanied by a decreased interaction of CRMP2 with Drp1, Miro 2, and Mitofusin 2, which are proteins involved in regulating mitochondrial morphology and motility. CRMP2 was hyperphosphorylated in postmortem brain tissues of AD patients, in brain lysates, and in cultured cortical neurons from the double transgenic APP/PS1 mice, an AD mouse model. CRMP2 hyperphosphorylation and dissociation from its binding partners correlated with increased Drp1 recruitment to mitochondria, augmented mitochondrial fragmentation, and reduced mitochondrial motility. (S)-lacosamide ((S)-LCM), a small molecule that binds to CRMP2, decreased its phosphorylation at Ser 522 and Thr 509/514, and restored CRMP2's interaction with Miro 2, Drp1, and Mitofusin 2. This was paralleled by decreased Drp1 recruitment to mitochondria, diminished mitochondrial fragmentation, and improved motility of the organelles. Additionally, (S)-LCM-protected cultured cortical AD neurons from cell death. Thus, our data suggest that CRMP2, in a phosphorylation-dependent manner, participates in the regulation of mitochondrial morphology and motility, and modulates neuronal survival in AD.

Indexed as

Alzheimer DiseaseAnimalsBrainHumansIntercellular Signaling Peptides and ProteinsMiceMice, TransgenicMitochondriaNerve Tissue ProteinsNeuronscollapsin response mediator protein-2Intercellular Signaling Peptides and ProteinsNerve Tissue ProteinsAlzheimer’s diseasecortical neuronsCRMP2mitochondrial morphologymitochondrial motilityneuronal cell death

Identifiers

PMID37174687
PMCPMC10177167
OpenAlexW4367627072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.